上海盟科药业股份有限公司 2025年度业绩快报公告

Financial Data Summary - The company reported total revenue of 141.77 million RMB for 2025, representing a year-on-year increase of 8.83% [1] - The net loss attributable to the parent company was 241.61 million RMB, a decrease in loss of 199.11 million RMB compared to the previous year [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was a loss of 250.27 million RMB, a decrease in loss of 208.91 million RMB year-on-year [1] Financial Position - As of the end of 2025, the company's total assets were 705.09 million RMB, a decrease of 16.96% year-on-year [2] - The equity attributable to the parent company was 205.54 million RMB, down 53.18% compared to the previous year [2] - The net asset value per share attributable to the parent company was 0.31 RMB, a decrease of 53.73% year-on-year [2] Operational Performance and Factors Affecting Results - The company currently has only one product, Kanti Zuoan tablets, in the commercialization stage, and is exploring a market development model combining self-operated teams and commercial distribution [3] - The company has implemented measures to control sales, research and management expenses, optimize organizational structure, and improve resource utilization, leading to a decrease in overall costs and expenses compared to the previous year [3] - The reduction in idle funds used for purchasing trading financial assets led to a decline in fair value changes, impacting the overall profit and loss [3] Changes in Key Financial Metrics - The company's operating profit decreased its loss by 43.59% year-on-year, while the total profit decreased its loss by 43.48% [4] - The net profit attributable to the parent company decreased its loss by 45.18%, and the net profit excluding non-recurring gains and losses decreased its loss by 45.50% [4] - The decline in equity attributable to the parent company and net asset value per share exceeded 30% due to ongoing investments in key research projects and sales promotions for Kanti Zuoan tablets, despite a reduction in loss scale [5]